Alternative splicing at the human glucuronosyltransferase 1 gene locus (UGT1) produces alternate isoforms UGT1A_i2s that control glucuronidation activity through proteinprotein interactions. Here, we hypothesized that UGT1A_i2s function into a complex protein network connecting other metabolic pathways with influence on cancer cell metabolism. This is based on a pathway enrichment analysis of proteomic data that identified several high-confidence candidate interaction proteins of UGT1A_i2 proteins in human tissues, namely the rate-limiting enzyme of glycolysis pyruvate kinase (PKM), which plays a critical role in cancer cell metabolism and tumor growth. The partnership of UGT1A_i2 and PKM2 was confirmed by co-immunoprecipitation in the HT115 colon cancer cells and was supported by a partial co-localization of these two proteins. In support of a functional role for this partnership, depletion of UGT1A_i2 proteins in HT115 cells enforced the Warburg effect with higher glycolytic rate at the expense of mitochondrial respiration, and led to lactate accumulation. Untargeted metabolomics further revealed a significantly altered cellular content of 58 metabolites including many intermediates derived from the glycolysis and TCA cycle pathways. These metabolic changes were associated with a greater migration potential. The potential relevance of our observations is supported by the down-regulation of UGT1A_i2s mRNA in colon tumors compared to normal tissues. Alternate UGT1A variants may thus be part of the expanding compendium of metabolic pathways involved in cancer biology directly contributing to the oncogenic phenotype of colon cancer cells. Findings uncover new aspects of UGT functions diverging from their transferase activity.
Introduction
The uridine diphospho-glucuronosyltransferases (UGTs) are critical enzymes involved in drug and carcinogen metabolism as well as in the homeostasis of a wide range of endogenous molecules such as bilirubin, steroids and lipids (Rouleau et al., 2014; Rowland et al., 2013) . UGT enzymes catalyze the transfer of the sugar moiety of uridine diphospho-glucuronic acid (UDPGlcA) to numerous lipophilic substrates, and this reaction leads to inactivation and favors elimination of metabolites through bile and urine. Together with other metabolizing enzymes and transporters, UGTs are increasingly recognized as key determinants of the interindividual variability in pharmacokinetic and pharmacodynamic outcomes of clinically important drugs (Stingl et al., 2014) . Findings also reveal that metabolic alterations in the glucuronidation pathway may determine the degree of exposure of an individual to toxic or carcinogenic substances over a long period determining individual susceptibility to diseases such as cancer, as well as its progression (Rouleau et al., 2014) .
Alternative splicing is a powerful mean of controlling gene expression but also creates novel proteins with distinct structural and functional features (Biamonti et al., 2014) .
Extensive analysis of human UGT genomic sequences by our group uncovered a new class of UGT alternate isoforms derived from the UGT1 locus. Novel transcripts are created by the inclusion of an alternative terminal exon (exon 5b) that leads to the production of nine shorter UGT1A proteins called isoforms 2 (or i2s) (Girard et al., 2007; Levesque et al., 2007) . Expression analyses revealed that UGT1A enzymes (referred to as isoforms 1 or i1s) and alternate UGT1A_i2s are co-produced in the same tissue structures of the liver, kidney, stomach, intestine and colon (Bellemare et al., 2011) . The This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on January 3, 2017 as DOI: 10.1124/mol.116.106161 at ASPET Journals on January 7, 2017 molpharm.aspetjournals.org Downloaded from MOL #106161 6 presence of exon 5b in the mRNA sequence causes a premature end of translation, and produces nine alternate UGT1A_i2s with different N-terminal regions (encoded by different exons 1) and lacking the transmembrane domain but comprising ten novel Cterminal amino acids (R 435 KKQQSGRQM 444 ). As a consequence, these alternate proteins lack transferase function with UDPGlcA but gain new biologic activity by negatively modulating cellular glucuronidation through direct protein-protein interaction with UGT1A enzymes. This represents a new mode of regulation of the UGT metabolic pathway (Bellemare et al., 2010a; Rouleau et al., 2014) .
Alternative splicing was shown to produce isoforms with vastly different interaction profiles (Yang et al., 2016) . Literature supports oligomerization of UGT enzymes and with other proteins such as cytochrome P450 (Miyauchi et al., 2015; Rouleau et al., 2014) . It raises the possibility of other cellular functions for alternate UGT1A proteins and perhaps, in disease processes like cancer. Indeed, the human protein interactome is of pivotal importance in the regulation of biological systems and was shown to contribute to different pathologies, particularly cancer (Mitsopoulos et al., 2015; Yang et al., 2016) .
These interactions are considered as promising therapeutic targets with selected protein-protein interaction inhibitors that have reached clinical development (Scott et al., 2016) . Previous untargeted proteomic experiments with human liver and kidney normal tissues revealed a partnership between UGT1A_i2s and enzymes of the scavenging pathway such as catalase (CAT) and peroxiredoxin (PRDX). By these interactions, UGT1A_i2 proteins likely interfere with oligomeric complex formation necessary for scavenging activity of CAT and PRDX (Rouleau et al., 2014) . Other proteins were identified as partners of UGT1A_i2s in human tissues, using an antibody that recognized This article has not been copyedited and formatted. The final version may differ from this version. (Gupta and Bamezai, 2010) . However, the potential influence of this crosstalk remains unknown. Besides, it also remains undefined which of the nine UGT1A_i2 proteins interact with these other proteins. We thus postulated that UGT1A_i2s might interact with PKM and influence its activity with potential consequences on cancer cell phenotypes given the role the PKM enzyme in the metabolic remodelling of cancer cells.
Cancer cells present a distinct metabolic phenotype also known as the Warburg effect (Li and Zhang, 2016; Warburg et al., 1927) . In this context, the splice variant of pyruvate kinase M2 (PKM2) has received great attention as the major PKM isoform expressed by dividing cancer cells (Anastasiou et al., 2012; Israelsen and Vander Heiden, 2015; Taniguchi et al., 2015) . In contrast, PKM1 is more abundant in healthy quiescent cells (Bluemlein et al., 2011; Zhan et al., 2015) . PKM2 is a rate limiting glycolytic enzyme and a key metabolic regulator, whereas a clear picture of its function in cancer is still unresolved . PKM2 favors aerobic glycolysis, in which glucose is preferentially catabolized to lactate, rather than fully metabolized to carbon dioxide via mitochondrial oxidative phosphorylation (OXPHOS) (Christofk et al., 2008a) . This process provides cancer cells with energy and precursors for the synthesis of nucleic acids, amino acids, and lipids to support cell division. Recent data indicate that overexpression of PKM2 in colon tumors connote poor outcome, as it is associated with advanced tumor stage and lymph node metastasis, and is essential for the aerobic This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on January 3, 2017 as DOI: 10.1124/mol.116.106161 at ASPET Journals on January 7, 2017 molpharm.aspetjournals.org
Downloaded from
MOL #106161 8 glycolysis of colon cancer cells in vitro (Cui and Shi, 2015; Yang et al., 2014; Yang et al., 2015; Zhou et al., 2012) .
In this work, we sought to expose potential metabolic and phenotypic changes associated with UGT1A_i2 proteins in a colon cancer cell model HT115, in which PKM2 is expressed in addition to several different UGT1A proteins, including UGT1A enzymes and alternative i2 isoforms. We initially confirmed the direct interaction of UGT1A_i2s with pyruvate kinase by co-immunoprecipitation (co-IP) in HT115 cell lysates. Compared to normal colon tissues, downregulation of UGT1A_i2s mRNA expression was established in colon tumors by quantitative PCR and RNA sequencing. Metabolic alterations associated with depletion of UGT1A_i2 protein levels stably induced by shRNA (targeting the exon 5b region common to all UGT1A_i2s) were then investigated by complementary approaches including untargeted metabolomics and extracellular flux assays to monitor glycolysis and oxidative phosphorylation. Findings reveal for the first time a significant remodelling of energy metabolism and cellular content of several metabolic intermediates in UGT1A_i2s depleted cancer cells, likely partially explained by a direct interaction with PKM2. These metabolic changes are further associated with a greater migration potential, suggesting that alternate UGT1A proteins might contribute to the oncogenic phenotype of colon cancer cells.
Materials and Method
Immunofluorescence HT115 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK) and grown as described (Bellemare et al., 2010b) . Cells grown on coverslips to 60% confluence were fixed with 4% formaldehyde (Sigma, Oakville, ON, Canada) for 15 min This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on January 3, 2017 as DOI: 10.1124/mol.116.106161 at ASPET Journals on January 7, 2017 molpharm.aspetjournals.org Downloaded from MOL #106161 9 at room temperature, and permeabilized with 0.5% TX-100 (Sigma) for 5 min. All solutions were prepared in phosphate-buffered saline (PBS). Cells were incubated for 1h30 at RT with primary antibodies diluted in 1% fetal bovine serum (FBS). Primary antibodies were anti-PKM2 (1:500; #3198S, Cell Signaling, Danvers, MA, USA) and the custom mouse monoclonal anti-i2s (1:100; #4C5E7; GenScript, Piscataway, NJ, USA) described in Rouleau et al. (Rouleau et al., 2016) . Detection was made with donkey anti- 
Immunoprecipitation and pathway enrichment analysis
Proteomics experiments in commercial pools of human liver and kidney tissues were conducted according to a previous study (Rouleau et al., 2014) . Data have been deposited in the PRIDE database under the accession number PXD000295. Briefly, immunoprecipitation was carried out using 1 mg total protein lysate of human liver or kidney S9 fractions (cytosol and microsomes) (Xenotech, Lenexa, KS, USA) with 4 µg anti-UGT1A_i2 #4863 antibody and Protein G-coated magnetic beads (Dynabeads; Life Technologies) for 15 hours at 4°C. Proteins were identified by mass spectrometry using a TripleTOF 5600 after on-beads trypsin digestion. Pathway enrichment analysis was performed with Cytoscape v3.3.0, using ClueGo v2.2.3 and CluePedia v1.2.3 apps (Bindea et al., 2013; Bindea et al., 2009; Shannon et al., 2003) . Pathways were retrieved from the KEGG database (updated on January 15, 2016) and an This article has not been copyedited and formatted. The final version may differ from this version.
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Detection of protein expression and complexes
Co-immunoprecipitations (co-IPs) to confirm partnership with PKM2 were conducted on HT115 cell lysates using the anti-UGT1A_i2s (#4863) and the anti-UGT1A_i1s (#9348) as described (Rouleau et al., 2014) . Protein complexes were subjected to SDS-PAGE and detected by Western blotting with UGT1A_i2s (#4863), biotinylated UGT1A_i1 (#9348), and PKM2 (#3198S, Cell Signaling) antibodies. Protein expression was also detected by Western blot. To monitor protein integrity and phosphorylation status,, cells were lysed in Tris buffered solution (175 mM Tris pH 7.4, 150 mM NaCl, 1% Igepal, 1mM DTT) supplemented with Complete protease inhibitor (Roche, Laval, Qc, Canada) and phosSTOP (Sigma). Proteins were revealed using anti-PKM1 (#7067P, Cell Signaling), anti-PKM2 (Cell Signaling), anti-phospho-PKM2 Y105 (#3827; Cell Signaling) and anti-phospho-PKM2 S37 (#11456; Signalway Antibody; College Park, MD, USA).
PKM2 dimers and tetramers were crosslinked according to (Wang et al., 2014) . Briefly, cell were lysed in PBS (pH 7.4) containing 0.5% Triton X-100 for 30 min, then centrifuged at 16 000 xg for 20 min to remove debris. Lysates were then diluted to 4 mg/mL and glutaraldehyde (final concentration 0.0035%) was added to permanently crosslink proteins. After 2 min of incubation at RT, the crosslinking reaction was stopped using Tris pH 8.0 (final concentration 50 mM). Finally, protein complexes were subjected to SDS-PAGE and revealed using anti-PKM2 (Cell Signaling). This article has not been copyedited and formatted. The final version may differ from this version. 
Metabolic profiling of HT115 colon cancer cells
Metabolic profiles were established for two HT115 cell lines, a reference HT115 cell line (CTR) and a HT115 cell line in which the expression of UGT1A_i2 proteins were stably repressed (>90%) using a shRNA specific to the exon 5b of UGT1A (KD) (Rouleau et al., 2014) . Cell lines were grown for a maximum of 15 passages and periodically tested for mycoplasmas. Cells were seeded at 2 x 10 6 cells in a 10 cm petri dish and allowed to adhere and proliferate for four days, with one growth medium change after two days.
Cells were trypsinized, centrifuged and counted, before being washed twice with icecold PBS and frozen on dry ice. Mass spectrometry analyses were performed by the West Coast Metabolomics Center (UC Davis, Davis, CA, USA) as reported (Fiehn et al., 2010; Fiehn et al., 2008) . Data were normalized for cell count and log-transformed prior to testing for statistical differences using two-sided Student's t-tests.
The analysis of extracellular flux was achieved on a Seahorse XF e 24 using glycolysis and mitochondria stress kits according to the manufacturer's instructions (Seahorse Bioscience, MA, USA). For the glycolysis stress kit, 100 μ L of cells at 2.0 x 10 6 cells/mL were seeded in the dedicated plates, and allowed to adhere for two hours in the incubator before adding 150 μ L of pre-warmed culture medium. Cells were grown overnight, rinsed twice with 1 mL Seahorse XF Base Medium (Seahorse Bioscience) Lactate was quantified with a Lactate Colorimetric/Fluorometric Assay Kit (BioVision, Milpitas, CA, USA). Cells were seeded at 0.6 x 10 6 cells per well in a 6-well plate for 48 hours, rinsed twice with fresh medium and 3 mL of medium was added per well.
Medium was sampled at 0, 60, 120 and 180 min and immediately frozen on dry ice.
Cells were then trypsinized and counted. A perchloric acid deproteinization kit (BioVision) was used prior to sample dilution and lactate dosage. Fluorescence (Ex/Em = 535/590 nm) was measured on a TECAN M-1000 (Tecan US Inc., Morrisville, NC, USA). Samples were measured in duplicate for each time point. Results represent the mean of two independent experiments and differences were assessed by Student's twosided T-tests.
Cellular phenotypes
For proliferation assays, HT115 cells were monitored for 8 days and counted using a TC10 automated cell counter (Bio-Rad, Hercules, California, USA) after addition of Trypan Blue (Sigma). Live cell proliferation assays were conducted on the xCELLigence (Margaillan et al., 2015) . RT-qPCR were performed using UGT1A specific primers for variants 2/3 (encoding UGT1A_i2s) as described (Bellemare et al., 2010b) . Each participant provided written consent, and the local ethic committee approved the study. RNA sequencing data (GSE80463) are from a previous study (Rouleau et al., submitted) and were collected from three pools of colon tissues, each containing total RNA from 5 individuals (normal tissues) or 3 individuals (tumor tissues).
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Results

Interaction of UGT1A_i2 proteins with PKM2 in colon cancer HT115 cells
Proteomics experiments in human liver and kidney tissues were conducted according to a previous study (Fig.1A) . The complete list of identified partners in both tissues is provided (Supplemental Tables 1 and 2) based on a previous report (Rouleau et al., 2014) . A pathway enrichment analysis of alternate UGT1A_i2 protein partners identified several enzymes linked to pyruvate metabolism, citrate metabolism and glycolysis pathway, including pyruvate kinase involved in glycolysis (Fig.1B) . We validated the interaction with pyruvate kinase by co-IP in the HT115 cell model that expresses endogenous PKM2, UGT1A_i2s as well as UGT1A_i1 enzymes. These experiments confirmed that PKM2 interacts specifically with the UGT1A_i2 proteins but not with UGT1A_i1 enzymes in HT115 cells (Fig.1C ). Since PKM2 primarily localized in the cytoplasm (Wang et al., 2014), we then sought to establish the cellular distribution of alternate UGT1A_i2 proteins along with PKM2 (Fig.1D) . A subset of UGT1A_i2s colocalized with PKM2 and supports the potential of UGT1A_i2s to interact with PKM2 in this cellular context.
Depletion of UGT1A_i2s enhances glycolytic activity and lactate production but reduces mitochondrial respiration in living colon cancer HT115 cells.
We next assessed the potential influence of UGT1A_i2s on glycolysis and compared HT115 colon cancer cells expressing low (KD) and high (reference or control) UGT1A_i2 levels ( Fig.2A ) (Rouleau et al., 2014) . Given that PKM2 and PKM1 expression is similar in both cell models (Supplemental Fig. 1) , we postulated that the cellular content in 029; Fig.2B ) in cell medium of KD cells compared to control cells supports a functional impact of UGT1A_i2s on PKM2 activity. We then used an extracellular flux analyzer to measure extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in living HT115 cells, which reflects glycolytic activity and mitochondrial respiration, respectively. A higher glycolytic activity in the UGT1A_i2s depleted cells was observed as evidenced by a 27% ECAR elevation after addition of glucose to the medium. The maximal glycolytic capacity (measured after addition of oligomycin) was also elevated by 30%, upholding greater utilization of the glycolysis pathway compared to control cells (Fig.2C,D) . In an assay challenging the mitochondrial capacity and measuring OCR, we detected a lower activity in KD cells supported by lower baseline (-27%) and lower maximal mitochondrial respiration rates (-39%; after addition of FCCP) in these cells compared to control cells ( Fig.2E,F) . Thus, repression of endogenous UGT1A_i2 levels led to higher glycolytic rate at the expense of mitochondrial respiration.
Depletion of UGT1A_i2s induces broad metabolic changes in colon cancer HT115 cells and a greater migration potential.
Given the changes in the energetic pathway induced by depletion of endogenous UGT1A_i2 levels, we extended these studies to global cell metabolism using untargeted metabolomics. A significant effect in the cellular levels of 58 metabolites was observed including many intermediates derived from the glycolysis and TCA cycle pathways.
These metabolites include unknown (n=34; data not shown) and known (n=24) metabolites (Fig.3,4) . Specifically, higher levels of glucose, fructose and citrate were This article has not been copyedited and formatted. The final version may differ from this version. observed, as well as decreased serine and glutamine cellular contents (Fig.3B ). Lower levels of several amino acids and some of their metabolites in KD cells were also noted ( Fig.3,4) . These metabolic changes were not associated with differences in cell growth assessed by cell counts, or doubling time determined by a live cell proliferation assay in normal culture conditions or after deprivation of main extracellular carbon sources, glucose and glutamine (Supplemental Fig.2) . A modest change was noted upon deprivation of the non-essential amino acids serine and glycine (13% longer doubling time; P<0.05; Fig.5A,B) . However, KD cells had a significant greater migration potential (wound closure: 72%; P<0.05) compared to control cells (50%) ( Fig.5C-E ). Using an array of extracellular matrix proteins, data further showed a modest but significantly reduced adhesion capacity for KD cells toward collagen I (13%), laminin (10%) and tenascin (11%), compared to control cells (Fig.5F ).
Downregulation of UGT1A_i2s mRNA expression in colon tumors compared to normal tissues
To evaluate the potential relevance of our observations using the HT115 model in which endogenous UGT1A_i2 levels were depleted, we studied UGT1A_i2s expression in colon tumors compared to normal tissues. Quantitative PCR expression of the alternative mRNA variants (v2/v3) encoding UGT1A_i2 proteins assessed in primary colon tumors and paired peritumoral normal tissues revealed that most tumors (4/6; 67%) had a reduced UGT1A_i2s expression compared to normal tissues (Fig.6A ). This observation was further confirmed using RNA sequencing data generated from an independent set of colon samples (Fold change = -20.5; P<0.05; Fig.6B ).
Discussion
It is now well established that there is a strong and multifaceted connection between cell metabolism and cancer (Li and Zhang, 2016; Vander Heiden et al., 2009 ), while alternative splice variants of many cancer-related genes directly contribute to the oncogenic phenotype (Oltean and Bates, 2014) . We showed that depletion of UGT1A_i2 (Anastasiou et al., 2012; Christofk et al., 2008a) . Our analysis of extracellular flux in real-time uncovered an enhanced glycolytic activity and a lower OXPHOS capacity for KD cells, which is in accordance with a rerouting of carbohydrates toward lactate instead of TCA cycle. We also observed accumulation of lactate in KD cell medium, further suggesting that the presence of UGT1A_i2 proteins interferes with the glycolytic pathway. Given that PKM2 and PKM1 expression is similar in both cell models (Supplemental Fig. 1A) , we investigated the status of PKM2 phosphorylation and oligomerization. Phosphorylation of PKM2 at position Y 105 , favoring lactate production by the less active dimeric PKM2 conformation, was slightly enhanced in KD relative to control cells (Supplemental Fig.1A) whereas the PKM2 tetramer/dimer ratios were similar between the two model cell lines, unsupportive of a modulation of PKM2 oligomeric state by UGT1A_i2s (Supplemental Fig.1B) . PKM2 may also be involved in other functions in tumorigenesis and metastasis, since PKM2 was shown to act in the nucleus by regulating gene expression (Wang et al., 2014; Yang et al., 2012) . However, our previous analysis of global gene expression in HT115 cell lines suggest that the KD of UGT1A_i2s does not induce significant perturbations in gene expression of glycolytic enzymes or of other metabolic pathways, including genes modulated by PKM2 and reported to modulate migration and epithelial-mesenchymal transition (Hamabe et al., 2014; Rouleau et al., 2014; Yang et al., 2014) . Consistently, levels of phospho-PKM2
(position S 37 ) involved in nuclear translocation and functions of PKM2, were not altered by a KD of UGT1A_i2s (Supplemental Fig.1) . Therefore, it may be envisioned that the interaction between PKM2 and alternate UGT1A_i2 proteins might influence PKM2 allosteric regulation. In line with this notion, similar functional interactions of PKM2 with other proteins such as the promyelocytic leukemia (PML) tumor suppressor protein, the prolactin receptor, and the phosphoprotein (pp60src)-associated protein kinase of Rous sarcoma virus led to reduced pyruvate kinase activity through allosteric regulation (Christofk et al., 2008b; Gao et al., 2013; Glossmann et al., 1981; Mazurek et al., 2001; Presek et al., 1980; Shimada et al., 2008; Varghese et al., 2010) . Whether this could be mediated by direct interactions with phosphorylated UGT1A_i2s (Basu et al., 2003; Basu et al., 2005; Volak and Court, 2010) or by a UGT1A_i2-dependent modulation of interactions between PKM2 and other allosteric modulators will necessitate additional investigations. From a therapeutic perspective PKM2 expression and activity can be regulated by inhibitors and activators that have been tested in vitro and in vivo (Dong et al., 2016) .
The greater migration potential provoked by UGT1A_i2s KD in HT115 cells is in line with a shift from oxidative metabolism to aerobic glycolysis reported in more aggressive colon cancer cells (Hussain et al., 2016) . Consistent with our observation that lactate accumulates in the medium of UGT1A_i2s KD compared to control cells; this oncometabolite was shown to act not only as a potent fuel (oxidative) but also function as a signalling molecule to stimulate tumor angiogenesis (Doherty and Cleveland, (Lu et al., 2015) . Cell migration is an early requirement for tumor metastasis (Findlay et al., 2014) , but is a complex phenomenon that involves cycling of adhesion and cell detachment (Kurniawan et al., 2016; Pankova et al., 2010; Tozluoglu et al., 2013) . Strongly adherent cells may increase their migration capacity through a decrease of their adhesion to extracellular matrix. While subtle, we observed a differential adhesion capacity of KD cells, namely for laminin, a non-collagenous extracellular matrix critical in colon cancer and linked to tumor angiogenesis, epithelial-mesenchymal transition and metastasis (Guess et al., 2009; Kitayama et al., 1999; Simon-Assmann et al., 2011) . Accordingly, this observation may partially explain the differential migration phenotype between low and high UGT1A_i2 expressing cell lines.
A potential limitation is the fact that metabolomics data were derived from a single timepoint, and thus represent the sum of numerous metabolic reactions that occurred in a 48-hour period. The cellular content of several metabolic intermediates from the glycolysis and TCA cycle pathways was changed in UGT1A_i2-depleted HT115 cells compared to control cells and are unlikely explained solely by the protein-protein interaction between UGT1A_i2s and PKM2. Additional partnerships observed by proteomics, such as those with enzymes of the gluconeogenesis and TCA cycle that require additional validation by co-IP, may also underlie these observations. Of note, data revealed a globally reduced pool of glucogenic amino acids in KD cells. This is consistent with the enhanced glycolytic potential induced by the KD and with the identification of additional i2 protein partners associated with gluconeogenesis, for This article has not been copyedited and formatted. The final version may differ from this version. and PCK2 ). Furthermore, the lower serine levels in KD cells compared to CTR suggested that the de novo serine synthesis pathway, critical for cancer cell proliferation and metabolism (Mehrmohamadi and Locasale, 2015; Yoon et al., 2015) , might be perturbed. We thus expected that serine and glycine deprivation would increase the metabolic pressure on glycolysis through a deviation of its intermediates. Although modest, a significantly decreased cellular proliferation for KD cells was observed in these conditions, compared to control cells. It remains unknown whether a specific UGT1A_i2 protein or several of those expressed in the HT115 cell model trigger the observed effects given that all UGT1A_i2s were simultaneously repressed by shRNA.
Additional cell models need to be established to further investigate our initial findings.
To the best of our knowledge, this is the first identification of a functional link between the UGT pathway and energy metabolism implying that alternate UGT1A proteins might be regulators of PKM2 with consequences on cancer cell metabolism and phenotype. It may be unexpected that a depletion of alternate UGT1A_i2s is sufficient to alter the metabolic program of colon cancer cells given the numerous, redundant, and efficacious mechanisms in place to limit pyruvate oxidation in cancer cells. In the face of these counteracting mechanisms, the metabolic effects of UGT1A_i2s depletion are rather impressive and may be explained in part by an interaction with the key glycolytic and multifunctional enzyme PKM2, and most likely with other metabolic enzymes. Although there was no change in UDPGlcA cell content between the two cell models, another possibility could involve the allosteric modulation by UDPGlcA and/or other UDP-sugars, as reported for other glycolytic enzymes (Wu et al., 2006) . It also remains to be MOL #106161 23 demonstrated whether UGT1A_i2s possess enzyme activity by utilizing other UDPsugars for instance. Alternatively, the effects observed on metabolism could be mediated through an impact on endogenous levels of key metabolic molecules that are unknown substrates of UGT enzymes repressed by UGT1A_i2s. Findings thus support that alternate UGT1A proteins are potential metabolic regulators of cancer cell metabolism and that they may contribute to the oncogenic phenotype of colon cancer cells. We conclude that alternate UGT proteins may be part of the expanding compendium of metabolic pathways involved in cancer biology. However, further investigations of UGT1A alternate proteins in cancer metabolism are required, as the crosstalk between global cell metabolism and the UGT pathway may likely constitute a key vulnerability in cancer cells that could be exploited.
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